Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac 13-valent pneumococcal conjugate vaccine in healthy subjects aged 2 months and above
NCT05092386Phase 1Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal disease (8 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Incidence of adverse reactions at 30 days. Started Jan 2023; status: completed.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05092386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092386.